drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific antibody)
drug_description
A subcutaneous GPRC5D×CD3 bispecific T‑cell–engaging monoclonal antibody that redirects T cells to kill malignant plasma cells in multiple myeloma.
nci_thesaurus_concept_id
C171840
nci_thesaurus_preferred_term
Talquetamab
nci_thesaurus_definition
A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T-cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.
drug_mesh_term
Talquetamab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Humanized CD3×GPRC5D bispecific antibody that binds CD3 on T cells and GPRC5D on malignant plasma cells, crosslinking them to form an immune synapse, activate TCR/CD3 signaling and cytokine release, and drive cytotoxic T‑cell–mediated killing of GPRC5D‑expressing myeloma cells (with limited expression on normal tissues).
drug_name
Talquetamab
nct_id_drug_ref
NCT06066346